Literature DB >> 3859460

HLA-DR antigens in primary biliary cirrhosis: lack of association.

M F Bassendine, P J Dewar, O F James.   

Abstract

A study of HLA-DR antigen in 75 patients with primary biliary cirrhosis has been carried out in order to test the hypothesis that genetic factors related to genes controlling immune responses might be important in the pathogenesis of primary biliary cirrhosis. The frequencies of HLA-DR locus antigens was not significantly different from those in 200 normal controls, nor were those of tissue antigens on the A and B loci. No HLA-DR antigen was significantly associated with the appearance of granulomata on liver biopsy (possibly good prognosis) or with raised serum bilirubin (possibly bad prognosis); nor was there any association between any HLA-DR antigen and adverse reactions to D-penicillamine treatment in 17 patients with such adverse reactions. It is concluded that genetic traits related to HLA antigens studied are probably not important in the aetiology of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3859460      PMCID: PMC1432751          DOI: 10.1136/gut.26.6.625

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Histocompatibility antigens in active chronic hepatitis and primary biliary cirrhosis.

Authors:  R M Galbraith; A L Eddleston; M G Smith; R Williams; R N McSween; G Watkinson; H Dick; L A Kennedy; J R Batchelor
Journal:  Br Med J       Date:  1974-09-07

2.  High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis.

Authors:  R M Galbraith; M Smith; R M Mackenzie; D E Tee; D Doniach; R Williams
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

3.  HL-A antigens as markers for disease susceptibility and autoimmunity in Graves' disease.

Authors:  F C Grumet; R O Payne; J Konishi; J P Kriss
Journal:  J Clin Endocrinol Metab       Date:  1974-12       Impact factor: 5.958

4.  Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis.

Authors:  T Feizi; R Naccarato; S Sherlock; D Doniach
Journal:  Clin Exp Immunol       Date:  1972-04       Impact factor: 4.330

5.  Primary biliary cirrhosis in twin sisters.

Authors:  M R Chohan
Journal:  Gut       Date:  1973-03       Impact factor: 23.059

6.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

7.  Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications.

Authors:  D Doniach; I M Roitt; J G Walker; S Sherlock
Journal:  Clin Exp Immunol       Date:  1966-07       Impact factor: 4.330

8.  HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis.

Authors:  H Miyamori; Y Kato; K Kobayashi; N Hattori
Journal:  Digestion       Date:  1983       Impact factor: 3.216

9.  Serum protein levels in primary biliary cirrhosis.

Authors:  R N MacSween; C H Horne; A J Moffat; H M Hughes
Journal:  J Clin Pathol       Date:  1972-09       Impact factor: 3.411

10.  A suppressor T cell of the mixed lymphocyte reaction in man specific for the stimulating alloantigen. Evidence that identity at HLA-D between suppressor and responder is required for suppression.

Authors:  E G Engleman; A J McMichael; M E Batey; H O McDevitt
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Genetics and genomics of primary biliary cirrhosis.

Authors:  Brian D Juran; Konstantinos N Lazaridis
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

Review 2.  Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving.

Authors:  Pietro Invernizzi
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

3.  Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis.

Authors:  Guanghua Rong; Renqian Zhong; Ana Lleo; Patrick S C Leung; Christopher L Bowlus; Guo-Xiang Yang; Chen-Yen Yang; Ross L Coppel; Aftab A Ansari; Dean A Cuebas; Howard J Worman; Pietro Invernizzi; Gregory J Gores; Gary Norman; Xiao-Song He; M Eric Gershwin
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

4.  Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group.

Authors:  R G Watson; P W Angus; M Dewar; B Goss; R B Sewell; R A Smallwood
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

5.  Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis.

Authors:  U Volta; L De Franceschi; N Molinaro; F Cassani; L Muratori; M Lenzi; F B Bianchi; A J Czaja
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

6.  Genomic variants associated with primary biliary cirrhosis.

Authors:  Carlo Selmi; Natalie J Torok; Andrea Affronti; M Eric Gershwin
Journal:  Genome Med       Date:  2010-01-26       Impact factor: 11.117

7.  DNA polymorphism of HLA class II genes in primary biliary cirrhosis.

Authors:  N Morling; K Dalhoff; L Fugger; J Georgsen; B Jakobsen; L Ranek; N Odum; A Svejgaard
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

8.  HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases.

Authors:  S Shimoda; M Nakamura; H Ishibashi; K Hayashida; Y Niho
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

Review 9.  Association of human leukocyte antigen class II with susceptibility to primary biliary cirrhosis: a systematic review and meta-analysis.

Authors:  Baodong Qin; Jiaqi Wang; Jia Chen; Yan Liang; Zaixing Yang; Renqian Zhong
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.